195 related articles for article (PubMed ID: 34895284)
21. Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score.
Bouquot M; Dohan A; Gayat E; Barat M; Glehen O; Pocard M; Rousset P; Eveno C
Ann Surg Oncol; 2018 Mar; 25(3):694-701. PubMed ID: 29192372
[TBL] [Abstract][Full Text] [Related]
22. Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.
Bartoška P; Antoš F; Vítek P; Marx J; Holečková P; Novotný M; Kengbaeva M
Rozhl Chir; 2020; 99(4):159-166. PubMed ID: 32545978
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
[TBL] [Abstract][Full Text] [Related]
24. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
[TBL] [Abstract][Full Text] [Related]
25. A nomogram prediction model of pseudomyxoma peritonei established based on new prognostic factors of HE stained pathological images analysis.
Ma R; Su YD; Yan FC; Lin YL; Gao Y; Li Y
Cancer Med; 2024 Mar; 13(6):e7101. PubMed ID: 38506243
[TBL] [Abstract][Full Text] [Related]
26. Optimal peritoneal cancer index cutoff point for predicting surgical resectability of pseudomyxoma peritonei in treatment-naive patients.
Bai M; Li Y; Pu H; Xu Y; Chen J; Xu H; Wei H; Liang G; Ma R; Feng J
World J Surg Oncol; 2024 Jan; 22(1):39. PubMed ID: 38297355
[TBL] [Abstract][Full Text] [Related]
27. Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery.
Hotta M; Minamimoto R; Gohda Y; Tajima T; Kiyomatsu T; Yano H
Eur Radiol; 2020 Aug; 30(8):4193-4200. PubMed ID: 32211961
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
29. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
[TBL] [Abstract][Full Text] [Related]
30. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
[TBL] [Abstract][Full Text] [Related]
31. Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
Di Fabio F; Mehta A; Chandrakumaran K; Mohamed F; Cecil T; Moran B
Ann Surg Oncol; 2016 Dec; 23(13):4316-4321. PubMed ID: 27380645
[TBL] [Abstract][Full Text] [Related]
32. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
[TBL] [Abstract][Full Text] [Related]
33. [The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):419-424. PubMed ID: 32482033
[No Abstract] [Full Text] [Related]
34. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
35. Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment.
Merrell DS; McAvoy TJ; King MC; Sittig M; Millar EV; Nieroda C; Metcalf JL; Blum FC; Testerman TL; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1723-1726. PubMed ID: 30770164
[TBL] [Abstract][Full Text] [Related]
36. Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
Robella M; Vaira M; Borsano A; Mossetti C; DE Simone M
Anticancer Res; 2018 Feb; 38(2):929-932. PubMed ID: 29374723
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
Kusamura S; Hutanu I; Baratti D; Deraco M
J Surg Oncol; 2013 Jul; 108(1):1-8. PubMed ID: 23720095
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of NCC-PMP2-C1: a novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells.
Noguchi R; Yoshimatsu Y; Sin Y; Ono T; Tsuchiya R; Yoshida H; Kiyono T; Yonemura Y; Kondo T
Hum Cell; 2024 Mar; 37(2):511-522. PubMed ID: 38143259
[TBL] [Abstract][Full Text] [Related]
39. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.
van Ruth S; Hart AA; Bonfrer JM; Verwaal VJ; Zoetmulder FA
Ann Surg Oncol; 2002 Dec; 9(10):961-7. PubMed ID: 12464587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
